Atlas Venture Life Science Advisors, LLC
An institutional investment manager in CAMBRIDGE, MA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 13, 2026. SEC CIK 1917529.
- Reported value$881.3m
- Positions7
Holdings: 7 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR | Common Stock | 501575104 | 327 | 37.1% | 2,847,541 | Reduced−1,730,467 | |
| Dyne Therapeutics, Inc.DYN | Common Stock | 26818M108 | 151 | 17.1% | 6,800,099 | Reduced−2,330,366 | |
| Sionna Therapeutics, Inc.SION | Common Stock | 829401108 | 132 | 15.0% | 2,995,602 | Unchanged | |
| Kailera Therapeutics, Inc.KLRA | Common Stock | 482931102 | 114 | 12.9% | 5,171,282 | New+5,171,282 | |
| Disc Medicine, Inc.IRON | Common Stock | 254604101 | 111 | 12.6% | 1,513,875 | Unchanged | |
| Q32 Bio, Inc.QTTB | Common Stock | 746964105 | 34.6 | 3.9% | 2,717,106 | Added+625,000 | |
| Korro Bio, Inc.KRRO | Common Stock | 500946108 | 12.7 | 1.4% | 962,884 | Reduced−174,265 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-095933 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.